GET DAILY SIGNALSWhy Did Array Technologies (ARRY) Stock Fall Over -35% Today?
Array Technologies (ARRY) plunged more than 35% today after its latest earnings report revealed weak profitability and significantly softer 2026 guidance than investors were expecting, despite decent revenue and a strong order book.
Key Takeaways
-
ARRY beat Q4 revenue expectations but showed a sharp year‑over‑year sales decline and a sizeable net loss.
-
Adjusted EBITDA for Q4 badly missed Wall Street estimates, highlighting ongoing margin and cost pressures.
-
2026 guidance for EPS and EBITDA came in well below analyst forecasts, signaling weaker‑than‑hoped earnings power over the next year.
-
The stock had already run up strongly into the print, so the underwhelming outlook triggered a large “sell‑the‑news” and valuation reset.
What Happened in Q4?
Array reported Q4 2025 revenue of about 226 million dollars, roughly 6% above analyst estimates but still almost 18% lower than the same quarter a year ago. Non‑GAAP EPS was essentially breakeven (around 0.01 dollars), only in line with expectations and down from the prior year, while the company posted a net loss of over 160 million dollars to common shareholders.
Adjusted EBITDA for the quarter was roughly 11 million dollars, nearly 30% below Wall Street’s forecast, implying a very thin margin and reinforcing worries that Array is struggling to convert its top line into profits. The quarter confirmed a broader trend: earnings have been falling faster than revenue, with operating margins compressing meaningfully over the last two years.
Why the 2026 Outlook Spooked Investors
For fiscal 2026, management guided to adjusted EPS of about 0.65–0.75 dollars, with the midpoint around 0.70 dollars—more than 20% below the roughly 0.86 dollars analysts were expecting. They also projected EBITDA around 215 million dollars, well under the 250–260 million dollar range many on the Street had penciled in.
This cautious outlook came even as Array highlighted positives like 40% full‑year 2025 revenue growth to roughly 1.28 billion dollars and a record 2.2 billion dollar order book, supported by international expansion and new products. The combination of strong backlog but weaker profitability guidance led investors to conclude that growth is not translating into the level of earnings previously assumed.
Sentiment, Valuation, and Bearish Positioning
The selloff also reflects where sentiment and positioning were before the report. ARRY shares had rallied strongly into February on hopes for a solar recovery and optimism around the company’s growth narrative, with some analysts already warning that revenue and margin expectations looked stretched. Options data had shown notable bearish call activity and growing concern about declining returns on capital, signaling that a downside reaction was likely if the company failed to meaningfully beat and raise.
When the numbers came in—soft EBITDA, cautious EPS guidance, and evidence of ongoing margin pressure—those worries were confirmed, and investors aggressively repriced the stock lower. The result was a drop of more than 35%, as the market reset Array’s valuation to reflect slower earnings growth and execution risk in a still‑choppy utility‑scale solar environment.
Tickeron AI Perspective
Contributor
Momentum Indicator for ARRY turns positive, indicating new upward trend
ARRY saw its Momentum Indicator move above the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 75 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ARRY just turned positive on October 27, 2026. Looking at past instances where ARRY's MACD turned positive, the stock continued to rise in 31 of 41 cases over the following month. The odds of a continued upward trend are 76%.
ARRY moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ARRY crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 63%.
Following a +40.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARRY advanced for three days, in 191 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for ARRY moved out of overbought territory on November 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 19 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 47 cases where ARRY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
ARRY broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARRY entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.462) is normal, around the industry mean (2.537). P/E Ratio (-6.099) is within average values for comparable stocks, (6.086). Projected Growth (PEG Ratio) (0.399) is also within normal values, averaging (1.699). Dividend Yield (0.000) settles around the average of (0.042) among similar stocks. P/S Ratio (0.543) is also within normal values, averaging (5.133).
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. ARRY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceutical drugs
Industry AlternativePowerGeneration
Advertisement